EU/3/14/1375: Orphan designation for the treatment of xeroderma pigmentosum
Table of contents
On 19 November 2014, orphan designation (EU/3/14/1375) was granted by the European Commission to Prof. Alain Taieb, France, for Pro-Pro-Thr-Val-Pro-Thr-Arg for the treatment of xeroderma pigmentosum.
The sponsorship was transferred to ProGeLife S.A.S., France, in June 2016.
Please note that this product was withdrawn from the Union Register of orphan medicinal products in February 2022 on request of the Sponsor.
Treatment of xeroderma pigmentosum
|Orphan designation status||
|EU designation number||
|Date of designation||
8 Rue Sainte Barbe
Tel. +33 6 42 72 84 44
Fax +33 4 91 99 85 99
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: